# Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis

> **NCT02124070** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **National Human Genome Research Institute (NHGRI)**

## Conditions studied

- Cystinosis
- Myopathy

## Interventions

- **DRUG:** rh Growth Hormone

## Key facts

- **NCT ID:** NCT02124070
- **Lead sponsor:** National Human Genome Research Institute (NHGRI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-03-26
- **Primary completion:** 2015-11-06
- **Final completion:** 2015-11-06
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02124070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02124070, "Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02124070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*